indication_id,agency,description,indication,cancer_type,approval_url,publication_date,therapy_name,therapy_approach,therapy_strategy,therapy_type,biomarker
ind:ema.adcetris:0,ema,"The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).","ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).",Hodgkin Lymphoma,https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf,2023-12-01,"['Vinblastine', 'Dacarbazine', 'Brentuximab Vedotin', 'Doxorubicin']",Combination Therapy,"['Vinca alkaloid chemotherapy', 'Nonclassical alkylating chemotherapy', 'target CD30 antigens', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['CD30 + [present]']
ind:ema.adcetris:1,ema,The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).,ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).,Hodgkin Lymphoma,https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf,2023-12-01,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:ema.adcetris:2,ema,The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.,"ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): (i) following ASCT, or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.",Hodgkin Lymphoma,https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf,2023-12-01,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:ema.adcetris:3,ema,The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.,ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.,Cutaneous T-cell Lymphoma,https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf,2023-12-01,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:ema.afinitor:0,ema,"The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf,2022-06-27,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.afinitor:0,ema,"The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf,2022-06-27,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.afinitor:0,ema,"The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf,2022-06-27,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:ema.akeega:0,ema,The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf,2023-06-02,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:ema.akeega:0,ema,The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf,2023-06-02,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:ema.akeega:0,ema,The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf,2023-06-02,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:ema.akeega:0,ema,The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf,2023-06-02,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:ema.alecensa:0,ema,The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf,2024-06-19,['Alectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.alecensa:1,ema,The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf,2024-06-19,['Alectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.alecensa:2,ema,The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.,Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf,2024-06-19,['Alectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.alunbrig:0,ema,The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.,Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf,2023-09-22,['Brigatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.alunbrig:1,ema,The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf,2023-09-22,['Brigatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.avastin:0,ema,"The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.","Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf,2023-03-17,"['Erlotinib', 'Bevacizumab']",Combination Therapy,"['EGFR inhibition', 'VEGF inhibition']","['Targeted therapy', 'Targeted therapy']",['EGFR p.L858R [present]']
ind:ema.avastin:0,ema,"The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.","Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf,2023-03-17,"['Erlotinib', 'Bevacizumab']",Combination Therapy,"['EGFR inhibition', 'VEGF inhibition']","['Targeted therapy', 'Targeted therapy']",['EGFR Exon 19 (Deletion) [present]']
ind:ema.ayvakyt:0,ema,The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.,AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.,Gastrointestinal Stromal Tumor,https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf,2024-02-06,['Avapritinib'],Monotherapy,['KIT inhibition'],['Targeted therapy'],['PDGFRA p.D842V [present]']
ind:ema.besponsa:0,ema,The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).,BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf,2024-02-14,['Inotuzumab ozogamicin'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],"['BCR::ABL1 []', 'CD22 + [present]']"
ind:ema.besponsa:0,ema,The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).,BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf,2024-02-14,['Inotuzumab ozogamicin'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['CD22 + [present]']
ind:ema.blincyto:0,ema,The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.,BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf,2023-12-06,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],['CD19 + [present]']
ind:ema.blincyto:0,ema,The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.,BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf,2023-12-06,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:ema.blincyto:1,ema,The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf,2023-12-06,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:ema.blincyto:2,ema,The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.,BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf,2023-12-06,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:ema.blincyto:3,ema,The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.,BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome-negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf,2023-12-06,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:ema.bosulif:0,ema,The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).,Bosulif is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf,2023-05-17,['Bosutinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.bosulif:1,ema,"The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+ CML previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are no considered appropriate treatment options.","Bosulif is indicated for the treatment of adult patients with CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.",Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf,2023-05-17,['Bosutinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.braftovi:0,ema,The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.,Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf,2024-09-05,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.braftovi:0,ema,The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.,Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf,2024-09-05,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.braftovi:1,ema,"The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF p.V600E variant, who have received prior systemic therapy. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.","Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.",Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf,2024-09-05,"['Cetuximab', 'Encorafenib']",Combination Therapy,"['EGFR inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.braftovi:2,ema,The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.,Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf,2024-09-05,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.caprelsa:0,ema,"The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.","Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.",Medullary Thyroid Cancer,https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf,2023-08-16,['Vandetanib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:ema.cotellic:0,ema,The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.,Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf,2023-03-06,"['Cobimetinib', 'Vemurafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.cotellic:0,ema,The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.,Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf,2023-03-06,"['Cobimetinib', 'Vemurafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.cyramza:0,ema,The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.,Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf,2022-12-13,"['Ramucirumab', 'Erlotinib']",Combination Therapy,"['VEGF/VEGFR inhibition', 'EGFR inhibition']","['Targeted therapy', 'Targeted therapy']",['EGFR oncogenic variants [present]']
ind:ema.taxotere:0,ema,The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.,TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf,2023-12-14,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.taxotere:0,ema,The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.,TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf,2023-12-14,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['ERBB2 amplification [present]']
ind:ema.enhertu:0,ema,The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.,Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:ema.enhertu:0,ema,The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.,Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.enhertu:1,ema,"The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. For the purposes of this indication, HER2-low is defined as a score of IHC 1+ or IHC 2+/ISH-, as assessed by a CE-marked IVD medical device or alternative valid test.",Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-low [present]']
ind:ema.enhertu:2,ema,The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.,Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.enhertu:2,ema,The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.,Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 oncogenic variants [present]']
ind:ema.enhertu:3,ema,The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.,Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.,Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:ema.enhertu:3,ema,The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.,Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.,Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf,2024-03-05,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.erbitux:0,ema,"The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.","Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.",Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf,2022-05-25,['Cetuximab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['Wild type KRAS [present]', 'Wild type HRAS [present]', 'EGFR positive [present]', 'Wild type NRAS [present]']"
ind:ema.erbitux:1,ema,"The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.","Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy.",Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf,2022-05-25,"['Irinotecan', 'Cetuximab']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Targeted therapy']","['Wild type KRAS [present]', 'Wild type HRAS [present]', 'EGFR positive [present]', 'Wild type NRAS [present]']"
ind:ema.erbitux:2,ema,"The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.","Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.",Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf,2022-05-25,"['Fluorouracil', 'Cetuximab', 'Oxaliplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'EGFR inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type KRAS [present]', 'Wild type HRAS [present]', 'EGFR positive [present]', 'Wild type NRAS [present]']"
ind:ema.faslodex:0,ema,"The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.","Faslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf,2022-08-31,['Fulvestrant'],Monotherapy,['Estrogen receptor inhibition'],['Hormone therapy'],['ER positive [present]']
ind:ema.faslodex:1,ema,"The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.","Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf,2022-08-31,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:ema.faslodex:1,ema,"The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.","Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf,2022-08-31,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.faslodex:1,ema,"The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.","Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf,2022-08-31,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:ema.gavreto:0,ema,The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.,Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf,2023-11-21,['Pralsetinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:ema.iressa:0,ema,The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.,IRESSA is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf,2023-07-17,['Gefitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:ema.giotrif:0,ema,The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.,GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf,2023-06-21,['Afatinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:ema.herceptin:0,ema,"The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.","Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:ema.herceptin:1,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.herceptin:2,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.herceptin:3,ema,"The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.","Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Anastrozole', 'Trastuzumab']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.herceptin:4,ema,"The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.","Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:ema.herceptin:5,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,"Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.herceptin:5,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,"Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.herceptin:6,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Carboplatin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.herceptin:7,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,"Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Trastuzumab', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.herceptin:0,ema,"The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.","Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.herceptin:1,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:2,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:3,ema,"The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.","Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Anastrozole', 'Trastuzumab']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:4,ema,"The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.","Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.herceptin:5,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,"Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:5,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,"Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:6,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Carboplatin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:7,ema,The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.,"Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Trastuzumab', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:8,ema,"The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.,Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Capecitabine', 'Trastuzumab', 'Cisplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.herceptin:8,ema,"The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.,Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Fluorouracil', 'Trastuzumab', 'Cisplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.herceptin:8,ema,"The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.,Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Capecitabine', 'Trastuzumab', 'Cisplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['ERBB2 amplification [present]']
ind:ema.herceptin:8,ema,"The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.,Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf,2023-03-17,"['Fluorouracil', 'Trastuzumab', 'Cisplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['ERBB2 amplification [present]']
ind:ema.ibrance:0,ema,"The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf,2023-06-06,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.ibrance:0,ema,"The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf,2023-06-06,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:ema.ibrance:0,ema,"The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf,2023-06-06,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:ema.ibrance:1,ema,"The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf,2023-06-06,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:ema.ibrance:1,ema,"The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf,2023-06-06,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.ibrance:1,ema,"The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf,2023-06-06,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:ema.glivec:0,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.,Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.glivec:1,ema,"The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.","Glivec is indicated for the treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.",Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.glivec:2,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.,Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.glivec:3,ema,The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).,Glivec is indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.glivec:4,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.,Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myelodysplastic Syndromes,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRA rearrangements [present]']
ind:ema.glivec:4,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.,Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myelodysplastic Syndromes,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRB rearrangements [present]']
ind:ema.glivec:4,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.,Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myeloproliferative Neoplasm,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRA rearrangements [present]']
ind:ema.glivec:4,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.,Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myeloproliferative Neoplasm,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRB rearrangements [present]']
ind:ema.glivec:5,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.,Glivec is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR_ rearrangement.,"Chronic Eosinophilic Leukemia, NOS",https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['FIP1L1::PDGFRA [present]']
ind:ema.glivec:6,ema,The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,Glivec is indicated for the treatment of the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).,Gastrointestinal Stromal Tumor,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['CD117 + [present]']
ind:ema.glivec:7,ema,The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.,Glivec is indicated for the treatment of the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.,Gastrointestinal Stromal Tumor,https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf,2023-11-20,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['CD117 + [present]']
ind:ema.iclusig:0,ema,"The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.","Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf,2022-10-21,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['ABL1 p.T315I [present]']
ind:ema.iclusig:1,ema,The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.,Iclusig is indicated in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf,2022-10-21,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.iclusig:1,ema,The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.,Iclusig is indicated in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf,2022-10-21,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],"['ABL1 p.T315I [present]', 'BCR::ABL1 []']"
ind:ema.imfinzi:0,ema,"The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.","IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on >= 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf,2024-08-13,['Durvalumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 1% [present]']
ind:ema.imfinzi:1,ema,"The European Medicines Agency (EMA) has authorized durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf,2024-08-13,"['Tremelimumab', 'Durvalumab', 'Carboplatin']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.imfinzi:2,ema,"The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).","IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf,2024-08-13,"['Durvalumab', 'Paclitaxel', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['dMMR [present]']
ind:ema.imfinzi:2,ema,"The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).","IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf,2024-08-13,"['Paclitaxel', 'Durvalumab', 'Carboplatin', 'Olaparib']",Combination Therapy,"['Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'PARP inhibition']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Targeted therapy']",['pMMR [present]']
ind:ema.imjudo:0,ema,"The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf,2024-03-13,"['Tremelimumab', 'Durvalumab', 'Carboplatin']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.jemperli:0,ema,The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.,JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.,Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf,2024-01-12,"['Carboplatin', 'Dostarlimab', 'Paclitaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['MSI-H [present]']
ind:ema.jemperli:0,ema,The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.,JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.,Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf,2024-01-12,"['Carboplatin', 'Dostarlimab', 'Paclitaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['dMMR [present]']
ind:ema.jemperli:1,ema,The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.,JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.,Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf,2024-01-12,['Dostarlimab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:ema.jemperli:1,ema,The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.,JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.,Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf,2024-01-12,['Dostarlimab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:ema.keytruda:0,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.,KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.keytruda:0,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.,KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'Wild type EGFR [present]', 'CD274 amplification [present]']"
ind:ema.keytruda:1,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.","KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Carboplatin', 'Pemetrexed', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.keytruda:1,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.","KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Cisplatin', 'Pemetrexed', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.keytruda:1,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.","KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Gemcitabine', 'Pembrolizumab', 'Cisplatin']",Combination Therapy,"['Antimetabolite', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.keytruda:1,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.","KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Pembrolizumab', 'Carboplatin', 'Gemcitabine']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antimetabolite']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.keytruda:1,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.","KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.keytruda:2,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung carcinoma whose tumors express PD-L1 with a >= 1% tumor proportion score (TPS) and who have recieved at least one prior chemotherapy regime. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving pembrolizumab.,KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 1% [present]']
ind:ema.keytruda:3,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.,KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS) >= 10.,Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 10 [present]']
ind:ema.keytruda:4,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.,"KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Head and Neck Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 1 [present]']
ind:ema.keytruda:4,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.,"KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Head and Neck Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Fluorouracil', 'Pembrolizumab', 'Carboplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:ema.keytruda:4,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.,"KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Head and Neck Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:ema.keytruda:5,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.,KEYTRUDA as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a >= 50% TPS and progressing on or after platinum -containing chemotherapy.,Head and Neck Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 50% [present]']
ind:ema.keytruda:6,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.,KEYTRUDA as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:ema.keytruda:6,ema,The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.,KEYTRUDA as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:ema.keytruda:7,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:ema.keytruda:7,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:ema.keytruda:8,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:ema.keytruda:8,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:ema.keytruda:8,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",Gastrointestinal Stromal Tumor,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:ema.keytruda:8,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",Gastrointestinal Stromal Tumor,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:ema.keytruda:8,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:ema.keytruda:8,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.","KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:ema.keytruda:9,ema,The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.,"KEYTRUDA, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS >= 10.",Esophageal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 (CPS) >= 10 [present]']
ind:ema.keytruda:9,ema,The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.,"KEYTRUDA, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS >= 10.",Esophageal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Fluorouracil', 'Pembrolizumab', 'Carboplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['PD-L1 (CPS) >= 10 [present]']
ind:ema.keytruda:10,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as a monotherapy for the adjuvant treatment after surgery, of adult patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.","KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['HER2-negative [present]', 'PR negative [present]', 'ER negative [present]']"
ind:ema.keytruda:11,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.","KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Paclitaxel', 'Pembrolizumab']",Combination Therapy,"['Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy']","['PR negative [present]', 'HER2-negative [present]', 'PD-L1 (CPS) >= 10 [present]', 'ER negative [present]']"
ind:ema.keytruda:11,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.","KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Pembrolizumab', 'Nab-paclitaxel']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Immunotherapy', 'Chemotherapy']","['PD-L1 (CPS) >= 10 [present]', 'PR negative [present]', 'HER2-negative [present]', 'ER negative [present]']"
ind:ema.keytruda:11,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.","KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Pembrolizumab', 'Carboplatin', 'Gemcitabine']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antimetabolite']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['PR negative [present]', 'HER2-negative [present]', 'PD-L1 (CPS) >= 10 [present]', 'ER negative [present]']"
ind:ema.keytruda:12,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.","KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.",Cervical Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:ema.keytruda:12,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.","KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.",Cervical Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Pembrolizumab', 'Paclitaxel', 'Bevacizumab', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'VEGF inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:ema.keytruda:13,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.","KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Pembrolizumab', 'Cisplatin', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Immunotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['HER2-positive [present]', 'PD-L1 (CPS) >= 1 [present]']"
ind:ema.keytruda:13,ema,"The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.","KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Trastuzumab', 'Carboplatin', 'Pembrolizumab', 'Fluorouracil']",Combination Therapy,"['HER2 inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Thymidylate synthase inhibition']","['Targeted therapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy']","['HER2-positive [present]', 'PD-L1 (CPS) >= 1 [present]']"
ind:ema.keytruda:14,ema,The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.,"KEYTRUDA, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['HER2-negative [present]', 'PD-L1 (CPS) >= 1 [present]']"
ind:ema.keytruda:14,ema,The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.,"KEYTRUDA, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf,2024-01-11,"['Fluorouracil', 'Pembrolizumab', 'Carboplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']","['HER2-negative [present]', 'PD-L1 (CPS) >= 1 [present]']"
ind:ema.kadcyla:0,ema,"The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.","Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf,2023-03-22,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:ema.kadcyla:0,ema,"The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.","Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf,2023-03-22,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.kadcyla:1,ema,"The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.","Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf,2023-03-22,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:ema.kadcyla:1,ema,"The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.","Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf,2023-03-22,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['ERBB2 amplification [present]']
ind:ema.kisqali:0,ema,"The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.","Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf,2023-10-17,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.kisqali:0,ema,"The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.","Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf,2023-10-17,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:ema.kisqali:0,ema,"The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.","Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf,2023-10-17,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:ema.kisqali:0,ema,"The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.","Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf,2023-10-17,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:ema.kisqali:0,ema,"The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.","Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf,2023-10-17,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.kisqali:0,ema,"The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.","Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf,2023-10-17,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:ema.krazati:0,ema,The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.,KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf,2024-03-13,['Adagrasib'],Monotherapy,['RAS inhibition'],['Targeted therapy'],['KRAS p.G12C [present]']
ind:ema.libtayo:0,ema,"The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.","LIBTAYO as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf,2024-01-12,['Cemiplimab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ROS1 [present]', 'Wild type EGFR [present]', 'Wild type ALK [present]', 'PD-L1 >= 50% [present]']"
ind:ema.libtayo:1,ema,"The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.","LIBTAYO in combination with platinum_based chemotherapy is indicated for the first_line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf,2024-01-12,"['Cemiplimab', 'Pemetrexed', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['PD-L1 >= 1% [present]', 'Wild type EGFR [present]', 'Wild type ALK [present]', 'Wild type ROS1 [present]']"
ind:ema.lorviqua:0,ema,The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.,Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf,2024-01-12,['Lorlatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.lorviqua:1,ema,The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.,Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf,2024-01-12,['Lorlatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.lumykras:0,ema,The European Medicines Agency (EMA) has authorized sotorasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and who have progressed after at least one prior line of systemic therapy.,LUMYKRAS as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf,2024-02-27,['Sotorasib'],Monotherapy,['RAS inhibition'],['Targeted therapy'],['KRAS p.G12C [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:0,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.","Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['HRD [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['HRD [present]']
ind:ema.lynparza:1,ema,"The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['HRD [present]']
ind:ema.lynparza:2,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.","Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'BRCA1 pathogenic variants [present]']"
ind:ema.lynparza:3,ema,"The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.","Lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'BRCA1 pathogenic variants [present]']"
ind:ema.lynparza:2,ema,"The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.","Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA2 pathogenic variants [present]', 'HER2-negative [present]']"
ind:ema.lynparza:3,ema,"The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.","Lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA2 pathogenic variants [present]', 'HER2-negative [present]']"
ind:ema.lynparza:4,ema,The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.,Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.,Pancreatic Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:4,ema,The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.,Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.,Pancreatic Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:5,ema,The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:ema.lynparza:5,ema,The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:ema.lynparza:5,ema,The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:ema.lynparza:5,ema,The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:ema.lynparza:6,ema,The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.,Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.,Endometrial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf,2024-08-20,"['Olaparib', 'Durvalumab']",Combination Therapy,"['PARP inhibition', 'PD-1/PD-L1 inhibition']","['Targeted therapy', 'Immunotherapy']",['pMMR [present]']
ind:ema.lytgobi:0,ema,The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.,Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,Intrahepatic Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf,2023-10-19,['Futibatinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR2::v [present]']
ind:ema.lytgobi:0,ema,The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.,Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,Intrahepatic Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf,2023-10-19,['Futibatinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR2 rearrangements [present]']
ind:ema.mabthera:0,ema,"The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.","MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.",Diffuse Large B-Cell Lymphoma,https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf,2023-11-29,"['Doxorubicin', 'Vincristine', 'Cyclophosphamide', 'Prednisolone', 'Rituximab']",Combination Therapy,"['Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Alkylating chemotherapy', 'Corticosteroid', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:ema.mabthera:0,ema,"The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.","MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.",Non-Hodgkin Lymphoma,https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf,2023-11-29,"['Doxorubicin', 'Vincristine', 'Cyclophosphamide', 'Prednisolone', 'Rituximab']",Combination Therapy,"['Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Alkylating chemotherapy', 'Corticosteroid', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:ema.mabthera:1,ema,"The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.","MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).",Diffuse Large B-Cell Lymphoma,https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf,2023-11-29,"['Doxorubicin', 'Etoposide', 'Vincristine', 'Corticosteroid', 'Cyclophosphamide', 'Rituximab', 'Cytarabine', 'Methotrexate']",Combination Therapy,"['Topoisomerase inhibition', 'Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Anti-inflammatory', 'Alkylating chemotherapy', 'CD20 inhibition', 'DNA Polymerase inhibition', 'Antifolate']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Hormone therapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:ema.mabthera:1,ema,"The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.","MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).",Non-Hodgkin Lymphoma,https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf,2023-11-29,"['Doxorubicin', 'Etoposide', 'Vincristine', 'Corticosteroid', 'Cyclophosphamide', 'Rituximab', 'Cytarabine', 'Methotrexate']",Combination Therapy,"['Topoisomerase inhibition', 'Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Anti-inflammatory', 'Alkylating chemotherapy', 'CD20 inhibition', 'DNA Polymerase inhibition', 'Antifolate']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Hormone therapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:ema.mabthera:1,ema,"The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.","MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).",Burkitt Lymphoma,https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf,2023-11-29,"['Doxorubicin', 'Etoposide', 'Vincristine', 'Corticosteroid', 'Cyclophosphamide', 'Rituximab', 'Cytarabine', 'Methotrexate']",Combination Therapy,"['Topoisomerase inhibition', 'Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Anti-inflammatory', 'Alkylating chemotherapy', 'CD20 inhibition', 'DNA Polymerase inhibition', 'Antifolate']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Hormone therapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:ema.mekinist:0,ema,The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.,Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,['Trametinib'],Monotherapy,['MEK inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:ema.mekinist:0,ema,The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.,Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,['Trametinib'],Monotherapy,['MEK inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:ema.mekinist:0,ema,The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.,Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.mekinist:1,ema,"The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.","Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",Melanoma,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.mekinist:0,ema,The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.,Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.mekinist:1,ema,"The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.","Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",Melanoma,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.mekinist:2,ema,The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.,Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.mekinist:2,ema,The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.,Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.mektovi:0,ema,The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf,2024-09-05,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.mektovi:0,ema,The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf,2024-09-05,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.mektovi:1,ema,The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.,Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf,2024-09-05,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.mylotarg:0,ema,"The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).","MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).",Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf,2023-11-20,"['Daunorubicin', 'Cytarabine', 'Gemtuzumab ozogamicin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'CD33 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD33 + [present]']
ind:ema.nerlynx:0,ema,The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf,2023-06-15,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['HER2-positive [present]', 'ER positive [present]', 'PR positive [present]']"
ind:ema.nerlynx:0,ema,The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf,2023-06-15,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['HER2-positive [present]', 'ER positive [present]']"
ind:ema.nerlynx:0,ema,The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf,2023-06-15,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['PR positive [present]', 'HER2-positive [present]']"
ind:ema.nerlynx:0,ema,The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf,2023-06-15,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['PR positive [present]', 'ERBB2 amplification [present]', 'ER positive [present]']"
ind:ema.nerlynx:0,ema,The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf,2023-06-15,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['ERBB2 amplification [present]', 'ER positive [present]']"
ind:ema.nerlynx:0,ema,The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf,2023-06-15,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['ERBB2 amplification [present]', 'PR positive [present]']"
ind:ema.opdivo:0,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'CTLA-4 inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Immunotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.opdivo:0,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Cisplatin', 'Pemetrexed', 'Ipilimumab', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.opdivo:0,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Paclitaxel', 'Ipilimumab', 'Carboplatin', 'Nivolumab']",Combination Therapy,"['Taxane-based chemotherapy', 'CTLA-4 inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.opdivo:1,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Paclitaxel', 'Nivolumab', 'Carboplatin']",Combination Therapy,"['Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:ema.opdivo:1,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Pemetrexed', 'Carboplatin', 'Nivolumab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:ema.opdivo:1,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Nivolumab', 'Cisplatin', 'Gemcitabine']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antimetabolite']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:ema.opdivo:2,ema,"The European Medicines Agency (EMA) has authorized nivolumab as a monotherapy for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) with tumor cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.","OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,['Nivolumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 1% [present]']
ind:ema.opdivo:3,ema,The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['MSI-H [present]']
ind:ema.opdivo:3,ema,The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['dMMR [present]']
ind:ema.opdivo:4,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.","OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",Esophageal Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:ema.opdivo:5,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable, advanced, or recurrent metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%. This indication is based on CA209648, a randomized, active-controlled, and open-label study where the choice of chemotherapy was fluorouracil and cisplatin.","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%",Esophageal Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Fluorouracil', 'Cisplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:ema.opdivo:6,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",Esophageal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Fluorouracil', 'Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['PD-L1 (CPS) >= 5 [present]', 'HER2-negative [present]']"
ind:ema.opdivo:6,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",Esophageal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy']","['PD-L1 (CPS) >= 5 [present]', 'HER2-negative [present]']"
ind:ema.opdivo:6,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Fluorouracil', 'Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['PD-L1 (CPS) >= 5 [present]', 'HER2-negative [present]']"
ind:ema.opdivo:6,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",Esophagogastric Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy']","['PD-L1 (CPS) >= 5 [present]', 'HER2-negative [present]']"
ind:ema.opdivo:6,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Fluorouracil', 'Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['PD-L1 (CPS) >= 5 [present]', 'HER2-negative [present]']"
ind:ema.opdivo:6,ema,"The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).","OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf,2024-03-21,"['Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy']","['PD-L1 (CPS) >= 5 [present]', 'HER2-negative [present]']"
ind:ema.opdualag:0,ema,The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.,Opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf,2024-02-21,"['Relatlimab', 'Nivolumab']",Combination Therapy,"['LAG-3 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['PD-L1 < 1% [present]']
ind:ema.orserdu:0,ema,"The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.","ORSERDU monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf,2024-02-14,['Elacestrant'],Monotherapy,['ER signaling inhibition'],['Hormone therapy'],"['ER positive [present]', 'HER2-negative [present]', 'ESR1 oncogenic variants [present]']"
ind:ema.pemazyre:0,ema,The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,Intrahepatic Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf,2023-09-12,['Elacestrant'],Monotherapy,['ER signaling inhibition'],['Hormone therapy'],['FGFR2::v [present]']
ind:ema.pemazyre:0,ema,The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.,Intrahepatic Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf,2023-09-12,['Elacestrant'],Monotherapy,['ER signaling inhibition'],['Hormone therapy'],['FGFR2 rearrangements [present]']
ind:ema.perjeta:0,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.","Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Cyclophosphamide', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.perjeta:0,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.","Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.perjeta:1,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.perjeta:1,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Paclitaxel', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.perjeta:1,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.perjeta:1,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.perjeta:1,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.perjeta:2,ema,"The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.","Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf,2024-04-05,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.phesgo:0,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.","Phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Cyclophosphamide', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.phesgo:0,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.","Phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Paclitaxel', 'Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Paclitaxel', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.phesgo:1,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.phesgo:2,ema,"The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.","Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf,2022-03-02,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.piqray:0,ema,"The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.","Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf,2023-10-26,"['Alpelisib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PIK3CA somatic variants [present]', 'HER2-negative [present]']"
ind:ema.piqray:0,ema,"The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.","Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf,2023-10-26,"['Alpelisib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PIK3CA somatic variants [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:ema.piqray:0,ema,"The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.","Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf,2023-10-26,"['Alpelisib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PIK3CA somatic variants [present]', 'ER positive [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:ema.retsevmo:0,ema,The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.,Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf,2024-05-28,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:ema.retsevmo:1,ema,The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).,Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).,Papillary Thyroid Cancer,https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf,2024-05-28,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:ema.retsevmo:2,ema,"The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.",Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC).,Medullary Thyroid Cancer,https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf,2024-05-28,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['RET p.M918T [present]']
ind:ema.retsevmo:3,ema,"The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.","Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf,2024-05-28,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:ema.revlimid:0,ema,The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.,Revlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.,Myeloproliferative Neoplasm,https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf,2024-01-08,['Lenalidomide'],Monotherapy,['Angiogenesis inhibition'],['Chemotherapy'],['5q deletion [present]']
ind:ema.rozlytrek:0,ema,The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.,"Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf,2024-07-03,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ROS1 [present]']
ind:ema.rozlytrek:1,ema,"The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.","Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf,2024-07-03,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:ema.rozlytrek:1,ema,"The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.","Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf,2024-07-03,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:ema.rozlytrek:1,ema,"The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.","Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf,2024-07-03,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:ema.rydapt:0,ema,"The European Medicines Agency (EMA) has authorized midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintence therapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. Midostaurin's product information further states that AML patients must have confirmation of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.","Rydapt is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.",Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf,2023-07-26,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3-ITD [present]']
ind:ema.scemblix:0,ema,The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.,Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf,2024-01-12,['Asciminib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.spexotras:0,ema,The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF p.V600E variant who require systemic therapy.,Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,"Low-Grade Glioma, NOS",https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf,2024-01-17,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.spexotras:1,ema,The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.,Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.,"High-Grade Glioma, NOS",https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf,2024-01-17,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.sprycel:0,ema,The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.,SPRYCEL is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf,2022-06-17,['Dasatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.sprycel:1,ema,The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.,SPRYCEL is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf,2022-06-17,['Dasatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.sprycel:1,ema,The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.,SPRYCEL is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf,2022-06-17,['Dasatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.sprycel:2,ema,The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.,SPRYCEL is indicated for the treatment of paediatric patients with newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf,2022-06-17,['Dasatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.sprycel:3,ema,"The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).",SPRYCEL is indicated for the treatment of paediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.,Acute Lymphoid Leukemia,https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf,2022-06-17,['Dasatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.tabrecta:0,ema,"The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf,2023-01-25,['Capmatinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Splice Site) [present]']
ind:ema.tabrecta:0,ema,"The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf,2023-01-25,['Capmatinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Deletion) [present]']
ind:ema.tafinlar:0,ema,The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.,Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,['Dabrafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:ema.tafinlar:0,ema,The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.,Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,['Dabrafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:ema.tafinlar:0,ema,The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.,Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.tafinlar:0,ema,The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.,Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.tafinlar:1,ema,"The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.","Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",Melanoma,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.tafinlar:1,ema,"The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.","Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",Melanoma,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.tafinlar:2,ema,The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.,Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:ema.tafinlar:2,ema,The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.,Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf,2024-03-07,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:ema.tagrisso:0,ema,The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.,TAGRISSO as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 19 (Deletion) [present]']
ind:ema.tagrisso:0,ema,The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.,TAGRISSO as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.L858R [present]']
ind:ema.tagrisso:1,ema,The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.,TAGRISSO as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:ema.tagrisso:2,ema,The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.,TAGRISSO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.T790M [present]']
ind:ema.tagrisso:3,ema,"The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,"['Osimertinib', 'Cisplatin']",Combination Therapy,"['EGFR inhibition', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['EGFR Exon 19 (Deletion) [present]']
ind:ema.tagrisso:3,ema,"The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,"['Osimertinib', 'Carboplatin']",Combination Therapy,"['EGFR inhibition', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['EGFR Exon 19 (Deletion) [present]']
ind:ema.tagrisso:3,ema,"The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,"['Osimertinib', 'Cisplatin']",Combination Therapy,"['EGFR inhibition', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['EGFR p.L858R [present]']
ind:ema.tagrisso:3,ema,"The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf,2024-07-23,"['Osimertinib', 'Carboplatin']",Combination Therapy,"['EGFR inhibition', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['EGFR p.L858R [present]']
ind:ema.talzenna:0,ema,"The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.","Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf,2024-01-16,['Talazoparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA1 pathogenic variants [present]', 'HER2-negative [present]']"
ind:ema.talzenna:0,ema,"The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.","Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf,2024-01-16,['Talazoparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA2 pathogenic variants [present]', 'HER2-negative [present]']"
ind:ema.tarceva:0,ema,The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.,Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf,2023-05-16,['Erlotinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:ema.tarceva:1,ema,The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.,Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf,2023-05-16,['Erlotinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:ema.tasigna:0,ema,The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (CML) in the chronic phase.,Tasigna is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf,2023-11-27,['Nilotinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.tasigna:1,ema,The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Nilotinib's product information further states that efficacy data in patients with CML in blast crisis are not available.,Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf,2023-11-27,['Nilotinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.tasigna:2,ema,The European Medicines Agency (EMA) has authorized nilotinib for the treatment of pediatric patients with chronic phase Phildelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.,Tasigna is indicated for the treatment of paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.,Chronic Myelogenous Leukemia,https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf,2023-11-27,['Nilotinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:ema.tecentriq:0,ema,"The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.","Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC (i) after prior platinum-containing chemotherapy, or (ii) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 5% [present]']
ind:ema.tecentriq:1,ema,The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.,Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.tecentriq:2,ema,"The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.","Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,"['Carboplatin', 'Paclitaxel', 'Atezolizumab', 'Bevacizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'VEGF inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Targeted therapy']",['EGFR somatic variants [present]']
ind:ema.tecentriq:2,ema,"The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.","Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,"['Carboplatin', 'Paclitaxel', 'Atezolizumab', 'Bevacizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'VEGF inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Targeted therapy']",['v::ALK [present]']
ind:ema.tecentriq:3,ema,The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.,"Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,"['Carboplatin', 'Atezolizumab', 'Nab-paclitaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['Wild type EGFR [present]']
ind:ema.tecentriq:3,ema,The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.,"Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,"['Carboplatin', 'Atezolizumab', 'Nab-paclitaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['Wild type ALK [present]']
ind:ema.tecentriq:3,ema,The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.,"Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,"['Carboplatin', 'Atezolizumab', 'Nab-paclitaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.tecentriq:4,ema,The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.,Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression >= 50% TC or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.tecentriq:4,ema,The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.,Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression >= 50% TC or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'PD-L1 >= 10% TIIC [present]', 'Wild type EGFR [present]']"
ind:ema.tecentriq:5,ema,The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.,Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['EGFR somatic variants [present]']
ind:ema.tecentriq:5,ema,The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.,Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['v::ALK [present]']
ind:ema.tecentriq:6,ema,The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.,Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf,2024-03-25,"['Atezolizumab', 'Nab-paclitaxel']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Immunotherapy', 'Chemotherapy']","['PD-L1 >= 1% [present]', 'ER negative [present]', 'PR negative [present]', 'HER2-negative [present]']"
ind:ema.tepmetko:0,ema,"The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf,2023-11-20,['Tepotinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Splice Site) [present]']
ind:ema.tepmetko:0,ema,"The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf,2023-11-20,['Tepotinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Deletion) [present]']
ind:ema.tibsovo:0,ema,The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132C [present]']
ind:ema.tibsovo:0,ema,The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132G [present]']
ind:ema.tibsovo:0,ema,The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132H [present]']
ind:ema.tibsovo:0,ema,The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132L [present]']
ind:ema.tibsovo:0,ema,The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132S [present]']
ind:ema.tibsovo:1,ema,The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.,Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132C [present]']
ind:ema.tibsovo:1,ema,The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.,Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132G [present]']
ind:ema.tibsovo:1,ema,The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.,Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132H [present]']
ind:ema.tibsovo:1,ema,The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.,Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132L [present]']
ind:ema.tibsovo:1,ema,The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.,Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf,2024-01-15,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132S [present]']
ind:ema.tremelimumab astrazeneca:0,ema,"The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf,2023-09-11,"['Pemetrexed', 'Carboplatin', 'Durvalumab', 'Tremelimumab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'CTLA-4 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.tremelimumab astrazeneca:0,ema,"The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf,2023-09-11,"['Pemetrexed', 'Durvalumab', 'Cisplatin', 'Tremelimumab']",Combination Therapy,"['Antifolate', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'CTLA-4 inhibition']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.tremelimumab astrazeneca:0,ema,"The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf,2023-09-11,"['Cisplatin', 'Durvalumab', 'Gemcitabine', 'Tremelimumab']",Combination Therapy,"['Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Antimetabolite', 'CTLA-4 inhibition']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.tremelimumab astrazeneca:0,ema,"The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf,2023-09-11,"['Tremelimumab', 'Carboplatin', 'Gemcitabine', 'Durvalumab']",Combination Therapy,"['CTLA-4 inhibition', 'Platinum-based chemotherapy', 'Antimetabolite', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.tremelimumab astrazeneca:0,ema,"The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf,2023-09-11,"['Tremelimumab', 'Nab-paclitaxel', 'Carboplatin', 'Durvalumab']",Combination Therapy,"['CTLA-4 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:ema.trisenox:0,ema,"The European Medicines Agency (EMA) has authorized arsenic trioxide for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.","RISENOX is indicated for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.",APL with PML-RARA,https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf,2023-05-25,['Arsenic trioxide'],Monotherapy,['PML::RARA inhibition'],['Targeted therapy'],['PML::RARA [present]']
ind:ema.trodelvy:0,ema,"The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.","Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf,2023-08-11,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'PR negative [present]', 'ER negative [present]']"
ind:ema.trodelvy:1,ema,"The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).","Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf,2023-08-11,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['ER positive [present]', 'HER2-negative [present]']"
ind:ema.trodelvy:1,ema,"The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).","Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf,2023-08-11,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['PR positive [present]', 'HER2-negative [present]']"
ind:ema.trodelvy:1,ema,"The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).","Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf,2023-08-11,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:ema.tukysa:0,ema,The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.,TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.,Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf,2023-08-21,"['Tucatinib', 'Capecitabine', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Thymidylate synthase inhibition', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.tyverb:0,ema,"The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.","Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf,2023-05-10,"['Capecitabine', 'Lapatinib']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:ema.tyverb:1,ema,"The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.","Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf,2023-05-10,"['Trastuzumab', 'Lapatinib']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition']","['Targeted therapy', 'Targeted therapy']","['PR negative [present]', 'HER2-positive [present]', 'ER positive [present]']"
ind:ema.tyverb:2,ema,"The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.","Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf,2023-05-10,"['Letrozole', 'Lapatinib']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-positive [present]', 'PR positive [present]']"
ind:ema.tyverb:0,ema,"The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.","Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf,2023-05-10,"['Capecitabine', 'Lapatinib']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['ERBB2 amplification [present]']
ind:ema.tyverb:1,ema,"The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.","Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf,2023-05-10,"['Trastuzumab', 'Lapatinib']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition']","['Targeted therapy', 'Targeted therapy']","['ER positive [present]', 'PR negative [present]', 'ERBB2 amplification [present]']"
ind:ema.tyverb:2,ema,"The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.","Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf,2023-05-10,"['Letrozole', 'Lapatinib']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'ERBB2 amplification [present]', 'PR positive [present]']"
ind:ema.vectibix:0,ema,"The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf,2022-07-06,"['Fluorouracil', 'Panitumumab', 'Oxaliplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'EGFR inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:ema.vectibix:0,ema,"The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf,2022-07-06,"['Irinotecan', 'Panitumumab', 'Fluorouracil']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:ema.vectibix:1,ema,"The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFIRI for the second-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf,2022-07-06,"['Irinotecan', 'Panitumumab', 'Fluorouracil']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:ema.vectibix:2,ema,"The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.","Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf,2022-07-06,['Panitumumab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:ema.venclyxto:0,ema,The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf,2023-10-31,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['TP53 somatic variants [present]']
ind:ema.venclyxto:0,ema,The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf,2023-10-31,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['TP53 deletion [present]']
ind:ema.venclyxto:0,ema,The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf,2023-10-31,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['17p deletion []']
ind:ema.venclyxto:1,ema,The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.,Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed chemoimmunotherapy and a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf,2023-10-31,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['Wild type TP53 [present]']
ind:ema.venclyxto:1,ema,The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.,Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed chemoimmunotherapy and a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf,2023-10-31,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['17p deletion []']
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Fulvestrant']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Fulvestrant']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:1,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.","Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Fulvestrant']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]', 'ER positive [present]']"
ind:ema.vitrakvi:0,ema,"The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.","VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf,2023-09-22,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:ema.vitrakvi:0,ema,"The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.","VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf,2023-09-22,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:ema.vitrakvi:0,ema,"The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.","VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",Any solid tumor,https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf,2023-09-22,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:ema.vizimpro:0,ema,The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.,"Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf,2024-02-21,['Dacomitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:ema.xalkori:0,ema,The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,XALKORI as monotherapy is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf,2024-09-24,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.xalkori:1,ema,The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,XALKORI as monotherapy is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf,2024-09-24,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.xalkori:2,ema,The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).,XALKORI as monotherapy is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf,2024-09-24,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ROS1 [present]']
ind:ema.xalkori:3,ema,The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).,XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).,Anaplastic Large Cell Lymphoma,https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf,2024-09-24,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.xalkori:4,ema,The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).,XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumour (IMT).,Inflammatory Myofibroblastic Tumor,https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf,2024-09-24,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.xospata:0,ema,"The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf,2023-11-07,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3-ITD [present]']
ind:ema.xospata:0,ema,"The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.,Acute Myeloid Leukemia,https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf,2023-11-07,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835Y [present]']
ind:ema.yervoy:0,ema,"The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf,2024-03-21,"['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'CTLA-4 inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Immunotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.yervoy:0,ema,"The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf,2024-03-21,"['Cisplatin', 'Pemetrexed', 'Ipilimumab', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.yervoy:0,ema,"The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf,2024-03-21,"['Paclitaxel', 'Ipilimumab', 'Carboplatin', 'Nivolumab']",Combination Therapy,"['Taxane-based chemotherapy', 'CTLA-4 inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:ema.yervoy:1,ema,The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf,2024-03-21,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['MSI-H [present]']
ind:ema.yervoy:1,ema,The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.,Colorectal Adenocarcinoma,https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf,2024-03-21,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['dMMR [present]']
ind:ema.yervoy:2,ema,"The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.","YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",Esophageal Squamous Cell Carcinoma,https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf,2024-03-21,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:ema.zelboraf:0,ema,The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.,Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation- positive unresectable or metastatic melanoma.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf,2023-07-18,['Vemurafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:ema.zelboraf:0,ema,The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.,Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation- positive unresectable or metastatic melanoma.,Melanoma,https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf,2023-07-18,['Vemurafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:ema.zydelig:0,ema,The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.,Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf,2023-06-23,"['Rituximab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['TP53 deletion [present]']
ind:ema.zydelig:0,ema,The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.,Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf,2023-06-23,"['Rituximab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['TP53 somatic variants [present]']
ind:ema.zydelig:0,ema,The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.,Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf,2023-06-23,"['Rituximab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['17p deletion []']
ind:ema.zykadia:0,ema,The European Medicines Agency (EMA) has authorized ceritinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf,2023-12-07,['Ceritinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.zykadia:1,ema,The European Medicines Agency (EMA) has authorized ceritinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf,2023-12-07,['Ceritinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:ema.tevimbra:0,ema,"The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.","Tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on >= 50% of tumor cells with no EGFR or ALK positive mutations and who have (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf,2024-07-25,"['Pemetrexed', 'Tislelizumab', 'Carboplatin']",Combination Therapy,"['Antifolate', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]', 'PD-L1 >= 50% [present]']"
ind:ema.tevimbra:0,ema,"The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.","Tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on >= 50% of tumor cells with no EGFR or ALK positive mutations and who have (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf,2024-07-25,"['Pemetrexed', 'Tislelizumab', 'Cisplatin']",Combination Therapy,"['Antifolate', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]', 'PD-L1 >= 50% [present]']"
ind:ema.rybrevant:0,ema,The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.,Rybrevant is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.,Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf,2024-07-11,"['Pemetrexed', 'Carboplatin', 'Amivantamab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['EGFR Exon 20 (Insertion) [present]']
ind:ema.rybrevant:1,ema,"The European Medicines Agency (EMA) has authorized amivantamab as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.","Rybrevant is indicated as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf,2024-07-11,['Amivantamab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 20 (Insertion) [present]']
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PIK3CA somatic variants [present]', 'HER2-negative [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PIK3CA amplification [present]', 'HER2-negative [present]', 'ER positive [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'AKT1 amplification [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'AKT1 somatic variants [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN nonsense variants [present]', 'HER2-negative [present]', 'ER positive [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PTEN frameshift variants [present]', 'HER2-negative [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN splice site variants [present]', 'ER positive [present]', 'HER2-negative [present]']"
ind:ema.truqap:0,ema,"The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.","TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf,2024-07-11,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PTEN deletion [present]', 'ER positive [present]']"
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR2::BICC1 [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR2::CASP7 [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3::TACC3 [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3::BAIAP2L1 [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.R248C [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.S249C [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.G370C [present]']
ind:ema.balversa:0,ema,"The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.","Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",Bladder Urothelial Carcinoma,https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf,2024-08-29,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.Y373C [present]']
ind:ema.vyloy:0,ema,"The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).","Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf,2024-09-23,"['Zolbetuximab', 'Fluorouracil', 'Oxaliplatin']",Combination Therapy,"['CLDN18.2 inhibition', 'Thymidylate synthase inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['CLDN18.2 >= 75% [present]', 'HER2-negative [present]']"
ind:ema.vyloy:0,ema,"The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).","Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.",Adenocarcinoma of the Gastroesophageal Junction,https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf,2024-09-23,"['Oxaliplatin', 'Capecitabine', 'Zolbetuximab']",Combination Therapy,"['Platinum-based chemotherapy', 'Thymidylate synthase inhibition', 'CLDN18.2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['HER2-negative [present]', 'CLDN18.2 >= 75% [present]']"
ind:hse.1086:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved afatinib for reimbursement as a monotherapy treatment option for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutation(s), as demonstrated by a validated test method.",Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf,2020-02-26,['Afatinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hse.1087:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved alectinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. This indication is specifically for patients whose tumors have been historically confirmed to be NSCLC with an ALK rearrangement identified by an approved and validated test method.,Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401.pdf,2021-01-06,['Alectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1087:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved alectinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This indication is specifically for patients whose tumors have been historically confirmed to be NSCLC with an ALK rearrangement identified by an approved and validated test method.,As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401.pdf,2021-01-06,['Alectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1088:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved asciminib for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase, who have been previously treated with two or more tyrosine kinase inhibitors (TKIs). The therapy regimen further states that hypersensitivity to asciminib or to any of the excipients, presence of the T315I mutation, and pregnancy / breastfeeding are exclusion criteria.","Treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase (CP), who have previously been treated with two or more tyrosine kinase inhibitors (TKIs).",Chronic Myelogenous Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/847-asciminib-therapy.pdf,2023-11-01,['Asciminib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:hse.1089:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved bosutinib for reimbursement as a treatment option for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib, and dasatinib are not considered appropriate treatment options.","Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib and dasatinib are not considered appropriate treatment options.",Chronic Myelogenous Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf,2021-03-22,['Bosutinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:hse.1090:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.",For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf,2021-10-22,['Brigatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1090:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.",Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf,2021-10-22,['Brigatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1091:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ceritinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.",Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf,2020-11-10,['Ceritinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1092:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cobimetinib in combination with vemurafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 mutation, as demonstrated by a validated test method.",Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib%20and%20vemurafenib%20therapy.pdf,2020-05-01,"['Cobimetinib', 'Vemurafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hse.1092:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cobimetinib in combination with vemurafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 mutation, as demonstrated by a validated test method.",Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib%20and%20vemurafenib%20therapy.pdf,2020-05-01,"['Cobimetinib', 'Vemurafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:hse.1093:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved crizotinib for reimbursement as a treatment option for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, and whose ALK rearrangement has been demonstrated by an accurate and validate test method.",Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf,2020-01-08,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1094:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved dabrafenib for reimbursement as a treatment option for the treatment of adults with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.,Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf,2021-06-23,['Dabrafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:hse.1094:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved dabrafenib for reimbursement as a treatment option for the treatment of adults with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.,Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf,2021-06-23,['Dabrafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:hse.1095:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved dacomitinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.,"Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf,2021-06-23,['Dacomitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hse.1096:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved encorafenib in combination with binimetinib for reimbursement as a treatment option for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.,Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf,2021-06-23,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hse.1096:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved encorafenib in combination with binimetinib for reimbursement as a treatment option for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.,Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf,2021-06-23,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:hse.1097:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.","As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf,2022-05-25,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ROS1 [present]']
ind:hse.1098:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved loralatinib for reimbursement as a monotherapy treatment option for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on (i) alectinib or ceritinib as the first ALK-targeted treatment or (ii) crizotinib and at least one other ALK-targeted treatment.","As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on (i) alectinib or ceritinib as the first ALK-targeted treatment or (ii) crizotinib and at least one other ALK-targeted treatment.",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf,2022-09-29,['Lorlatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1098:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved loralatinib for reimbursement as a monotherapy treatment option for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.,As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf,2022-09-29,['Lorlatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hse.1099:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin in combination with standard daunorubicin and cytarabine induction chemotherapy for reimbursement as a treatment option for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.,Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.,Acute Myeloid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf,2023-12-08,"['Midostaurin', 'Cytarabine', 'Daunorubicin']",Combination Therapy,"['FLT3 inhibition', 'DNA Polymerase inhibition', 'DNA Polymerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['FLT3-ITD [present]']
ind:hse.1100:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.","Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf,2022-02-09,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['HER2-positive [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1100:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.","Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf,2022-02-09,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['HER2-positive [present]', 'ER positive [present]']"
ind:hse.1100:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.","Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf,2022-02-09,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['PR positive [present]', 'HER2-positive [present]']"
ind:hse.1100:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.","Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf,2022-02-09,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['PR positive [present]', 'ERBB2 amplification [present]', 'ER positive [present]']"
ind:hse.1100:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.","Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf,2022-02-09,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['ERBB2 amplification [present]', 'ER positive [present]']"
ind:hse.1100:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.","Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf,2022-02-09,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['ERBB2 amplification [present]', 'PR positive [present]']"
ind:hse.1101:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Niraparib in combination with abiraterone acetate (Akeega) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf,2023-11-01,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hse.1101:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Niraparib in combination with abiraterone acetate (Akeega) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf,2023-11-01,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hse.1101:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Niraparib in combination with abiraterone acetate (Akeega) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf,2023-11-01,"['Prednisolone', 'Abiraterone acetate', 'Niraparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['HRD [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['HRD [present]']
ind:hse.1102:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.","Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf,2023-09-01,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['HRD [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.","Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Ovarian Epithelial Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",High-Grade Serous Fallopian Tube Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.","Maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer who are in response (complete response or partial) to platinum-based chemotherapy",Peritoneal Serous Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1103:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hse.1103:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hse.1103:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hse.1103:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.,Prostate Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf,2023-03-01,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hse.1104:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).,Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf,2024-03-01,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.T790M [present]']
ind:hse.1104:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.,First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf,2024-03-01,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hse.1104:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the adjuvant treatment after complete tumor resection for adult patients with stae IB-IIIA non-small cell lung cancer (NSCLC) whose tumor has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.,As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf,2024-03-01,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 19 (Deletion) [present]']
ind:hse.1104:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the adjuvant treatment after complete tumor resection for adult patients with stae IB-IIIA non-small cell lung cancer (NSCLC) whose tumor has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.,As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf,2024-03-01,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.L858R [present]']
ind:hse.1105:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ponatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib, nilotinib, and bosutinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.","Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib, nilotinib and bosutinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",Chronic Myelogenous Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf,2021-06-21,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['ABL1 p.T315I [present]']
ind:hse.1105:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved ponatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.,Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf,2021-06-21,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 []']
ind:hse.1105:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved ponatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.,Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf,2021-06-21,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],"['ABL1 p.T315I [present]', 'BCR::ABL1 []']"
ind:hse.1106:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved talazoparib for reimbursement as a monotherapy treatment option for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.","Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf,2023-09-06,['Talazoparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA1 pathogenic variants [present]', 'HER2-negative [present]']"
ind:hse.1106:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved talazoparib for reimbursement as a monotherapy treatment option for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.","Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf,2023-09-06,['Talazoparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA2 pathogenic variants [present]', 'HER2-negative [present]']"
ind:hse.1107:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.,Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf,2021-11-11,"['Trametinib', 'Dabrafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hse.1107:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.","Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf,2021-11-11,"['Trametinib', 'Dabrafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hse.1107:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.,Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf,2021-11-11,"['Trametinib', 'Dabrafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:hse.1107:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.","Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.",Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf,2021-11-11,"['Trametinib', 'Dabrafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:hse.1108:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.,Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf,2020-01-08,['Vemurafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:hse.1108:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.,Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,Melanoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf,2020-01-08,['Vemurafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:hse.1109:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf,2021-03-03,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['TP53 somatic variants [present]']
ind:hse.1109:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf,2021-03-03,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['TP53 deletion [present]']
ind:hse.1109:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf,2021-03-03,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['17p deletion []']
ind:hse.1109:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.,Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf,2021-03-03,['Venetoclax'],Monotherapy,['BCL2 inhibition'],['Targeted therapy'],['Wild type TP53 [present]']
ind:hse.1110:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.,"As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naive and have del(17p) and/or TP53-mutated disease.",Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf,2023-09-12,['Zanubrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['TP53 somatic variants [present]']
ind:hse.1110:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.,"As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naive and have del(17p) and/or TP53-mutated disease.",Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf,2023-09-12,['Zanubrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['TP53 deletion [present]']
ind:hse.1110:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.,"As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naive and have del(17p) and/or TP53-mutated disease.",Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf,2023-09-12,['Zanubrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['17p deletion []']
ind:hse.1111:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.,As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf,2023-12-13,['Acalabrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['TP53 somatic variants [present]']
ind:hse.1111:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.,As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf,2023-12-13,['Acalabrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['TP53 deletion [present]']
ind:hse.1111:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.,As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf,2023-12-13,['Acalabrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['17p deletion []']
ind:hse.1112:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.",As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf,2022-11-28,['Ibrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['TP53 somatic variants [present]']
ind:hse.1112:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.",As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf,2022-11-28,['Ibrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['TP53 deletion [present]']
ind:hse.1112:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.",As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf,2022-11-28,['Ibrutinib'],Monotherapy,['BTK inhibition'],['Targeted therapy'],['17p deletion []']
ind:hse.1113:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.,In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf,2019-02-11,"['Rituximab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['TP53 somatic variants [present]']
ind:hse.1113:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.,In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf,2019-02-11,"['Rituximab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['TP53 deletion [present]']
ind:hse.1113:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.,In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf,2019-02-11,"['Rituximab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['17p deletion []']
ind:hse.1114:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.,Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf,2023-06-01,"['Nivolumab', 'Ipilimumab']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'CTLA-4 inhibition']","['Immunotherapy', 'Immunotherapy']",['MSI-H [present]']
ind:hse.1114:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.,Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf,2023-06-01,"['Nivolumab', 'Ipilimumab']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'CTLA-4 inhibition']","['Immunotherapy', 'Immunotherapy']",['dMMR [present]']
ind:hse.1115:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.,First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1115:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.,First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'Wild type EGFR [present]', 'CD274 amplification [present]']"
ind:hse.1115:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy whose tumors express PD-L1 with a combined positive score (CPS) >= 10.,As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) >= 10.,Bladder Urothelial Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 10 [present]']
ind:hse.1115:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.,As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1,Head and Neck Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 1 [present]']
ind:hse.1115:3,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.","As monotherapy for the treatment of recurrent, or metastatic cervical cancer with disease progression on or after chemotherapy in adults whose tumours express PD-L1 with a CPS >= 1",Cervical Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 1 [present]']
ind:hse.1115:4,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).,First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:hse.1115:4,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).,First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:hse.1116:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf,2023-04-28,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:hse.1116:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf,2023-04-28,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:hse.1116:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf,2023-04-28,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:hse.1117:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of adult patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf,2023-04-28,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:hse.1117:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of adult patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf,2023-04-28,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:hse.1117:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of adult patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.","For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf,2023-04-28,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:hse.1118:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved gefitinib monotherapy for reimbursement for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.,Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf,2020-04-29,['Gefitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hse.1119:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.,First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf,2021-03-10,['Erlotinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hse.1119:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for switch maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy.,Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf,2021-03-10,['Erlotinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hse.1120:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either (i) received prior therapy for locally advanced or metastatic disease or (ii) developed disease recurrence during or within six months of completing adjuvant therapy.","Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (i) Received prior therapy for locally advanced or metastatic disease, or (ii) Developed disease recurrence during or within six months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/trastuzumab-emtansine-kadcyla%C2%AE-21-days.pdf,2017-09-20,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1121:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.","Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf,2020-10-23,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1121:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.","Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf,2020-10-23,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hse.1121:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.","Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf,2020-10-23,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:hse.1121:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.","Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf,2020-10-23,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:hse.1121:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.","Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf,2020-10-23,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hse.1121:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.","Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf,2020-10-23,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:hse.1122:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.","Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1122:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.","Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hse.1122:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.","Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1122:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.","Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1122:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.","Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hse.1122:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.","Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1122:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.","Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:hse.1122:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.","Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hse.1122:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.","Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf,2020-08-19,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:hse.1123:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved inotuzumab ozogamicin for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). The indication further states that adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).,Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf,2021-11-19,['Inotuzumab ozogamicin'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['CD22 + [present]']
ind:hse.1123:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved inotuzumab ozogamicin for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). The indication further states that adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).,Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf,2021-11-19,['Inotuzumab ozogamicin'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],"['BCR::ABL1 []', 'CD22 + [present]']"
ind:hse.1124:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of pediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.,As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/p567-blinatumomab-paediatric-therapy.pdf,2019-07-16,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:hse.1125:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ESHAP (etoposide, cisplatin, and cytarabine) for reimbursement as a treatment option for the treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.",Treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma,Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf,2024-08-24,"['Cisplatin', 'Etoposide', 'Brentuximab Vedotin', 'Cytarabine']",Combination Therapy,"['Platinum-based chemotherapy', 'Topoisomerase inhibition', 'target CD30 antigens', 'DNA Polymerase inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['CD30 + [present]']
ind:hse.1126:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. According to the EMA product information for this indication, this indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.","Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Cyclophosphamide', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1126:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. According to the EMA product information for this indication, this indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.","Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1126:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1126:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Paclitaxel', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1126:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1126:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1126:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",Pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf,2023-08-10,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1127:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for reimbursement as a treatment option for the treatment of patients aged 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukemia.","Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukaemia",Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf,2023-07-29,"['Daunorubicin', 'Cytarabine', 'Gemtuzumab ozogamicin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'CD33 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD33 + [present]']
ind:hse.1128:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and carboplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.,Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf,2022-07-04,"['Carboplatin', 'Pemetrexed', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1129:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and cisplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.,Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf,2022-12-19,"['Cisplatin', 'Pemetrexed', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1130:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved durvalumab as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 >= 1% on tumor cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).","As monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf,2023-09-04,['Durvalumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 1% [present]']
ind:hse.1131:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.,Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf,2024-06-14,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['EGFR somatic variants [present]']
ind:hse.1131:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.,Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf,2024-06-14,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['v::ALK [present]']
ind:hse.1131:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.,Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression >= 5%.,Bladder Urothelial Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf,2024-06-14,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 5% [present]']
ind:hse.1131:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf,2024-06-14,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1131:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf,2024-06-14,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'PD-L1 >= 10% TIIC [present]', 'Wild type EGFR [present]']"
ind:hse.1131:3,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.,Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf,2024-06-14,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1132:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab emtansine as a single agent for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.","As a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf,2024-02-23,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1133:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with carboplatin and 5-fluorouracil for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.,"Pembrolizumab is indicated, in combination with CARBOplatin and 5-Fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1.",Head and Neck Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf,2023-11-21,"['Fluorouracil', 'Pembrolizumab', 'Carboplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hse.1134:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with cisplatin and 5-fluorouracil for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.,"Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1.",Head and Neck Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf,2023-04-26,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hse.1135:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, carboplatin, and paclitaxel for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.",First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf,2023-12-14,"['Paclitaxel', 'Ipilimumab', 'Carboplatin', 'Nivolumab']",Combination Therapy,"['Taxane-based chemotherapy', 'CTLA-4 inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:hse.1136:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, carboplatin, and pemetrexed for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.",First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf,2022-01-25,"['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'CTLA-4 inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Immunotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:hse.1137:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, cisplatin, and pemetrexed for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.",First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf,2022-01-25,"['Cisplatin', 'Pemetrexed', 'Ipilimumab', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:hse.1138:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab in combination with nab-paclitaxel for reimbursement as a treatment option for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.,Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf,2022-12-16,"['Atezolizumab', 'Nab-paclitaxel']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Immunotherapy', 'Chemotherapy']","['PD-L1 >= 1% [present]', 'ER negative [present]', 'PR negative [present]', 'HER2-negative [present]']"
ind:hse.1139:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf,2022-10-04,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:hse.1140:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) as part of the consolidation therapy.,As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf,2022-05-06,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],"['BCR::ABL1 []', 'CD19 + [present]']"
ind:hse.1141:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab and trastuzumab (phesgo) in combination with paclitaxel and carboplatin for reimbursement as a treatment option for the treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.","Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf,2023-08-10,"['Carboplatin', 'Trastuzumab', 'Paclitaxel', 'Pertuzumab']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1142:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.,Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy,Cutaneous T-cell Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf,2022-12-20,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:hse.1142:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous hematopoietic stem cell transplant (ASCT).,Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).,Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf,2022-12-20,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:hse.1142:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following autologous stem cell transplant (ASCT).,Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT),Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf,2022-12-20,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:hse.1142:3,hse,The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.,Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option,Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf,2022-12-20,['Brentuximab Vedotin'],Monotherapy,['target CD30 antigens'],['Targeted therapy'],['CD30 + [present]']
ind:hse.1143:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin's lymphoma (HL).",Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL),Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf,2020-11-12,"['Brentuximab Vedotin', 'Etoposide', 'Ifosfamide', 'Carboplatin']",Combination Therapy,"['target CD30 antigens', 'Topoisomerase inhibition', 'Alkylating chemotherapy', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']","['HER2-negative [present]', 'CD30 + [present]']"
ind:hse.1144:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg) in combination with platinum and flouropyrimidine-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.,"Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.",Esophageal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/739-pembrolizumab-200mg-cisplatin-80mg-m2-and-5-fluorouracil-infusional-therapy.pdf,2024-01-26,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 (CPS) >= 10 [present]']
ind:hse.1144:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg) in combination with platinum and flouropyrimidine-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.,"Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.",Adenocarcinoma of the Gastroesophageal Junction,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/739-pembrolizumab-200mg-cisplatin-80mg-m2-and-5-fluorouracil-infusional-therapy.pdf,2024-01-26,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['HER2-negative [present]', 'PD-L1 (CPS) >= 10 [present]']"
ind:hse.1145:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab (480mg) in combination with flouropyrimidine and platinum-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (OSCC) with tumor cell programmed death ligang 1 (PD-L1) expression >= 1%.","Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression >= 1%.",Esophageal Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/832-nivolumab-cisplatin.pdf,2024-01-08,"['Fluorouracil', 'Cisplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1146:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680 mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.,Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf,2024-03-26,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['EGFR somatic variants [present]']
ind:hse.1146:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680 mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.,Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf,2024-03-26,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['v::ALK [present]']
ind:hse.1146:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumors have a PD-L1 expression >= 5%.","Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%",Bladder Urothelial Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf,2024-03-26,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 5% [present]']
ind:hse.1146:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf,2024-03-26,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1146:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf,2024-03-26,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'PD-L1 >= 10% TIIC [present]', 'Wild type EGFR [present]']"
ind:hse.1146:3,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 50% tumor cells and who do not have EGFR mutant or ALK-positive NSCLC.,Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf,2024-03-26,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1147:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable or metastatic carcinoma of the oesophagus or HER2-negative gastro-osophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.,"Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.",Adenocarcinoma of the Gastroesophageal Junction,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/839-pembrolizumab-and-folfox-6-modified-therapy.pdf,2024-01-26,"['Pembrolizumab', 'Fluorouracil', 'Oxaliplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Thymidylate synthase inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['HER2-negative [present]', 'PD-L1 (CPS) >= 10 [present]']"
ind:hse.1148:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory B cell precusor (BCP) Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) who have received no prior salvage treatment for relapsed / refractory (R/R) disease and are considered eligible for transplant (e.g., as a bridge-to-transplant).",Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).,Acute Lymphoid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf,2022-10-04,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],['BCR::ABL1 []']
ind:hse.1149:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with paclitaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to, or are deemed clinically unsuitable for docetaxel.","Pertuzumab/trastuzumab (Phesgo) is indicated in combination with PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf,2023-08-10,"['Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1150:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and paclitaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to, or are deemed clinically unsuitable for docetaxel.","Pertuzumab is indicated in combination with trastuzumab and PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf,2023-08-10,"['Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1151:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.","Pertuzumab/ trastuzumab (Phesgo) is indicated in combination with DOCEtaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf,2023-08-10,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1152:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.","Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf,2023-08-10,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1153:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with vinorelbine for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.","Pertuzumab/trastuzumab (Phesgo) and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/798-pertuzumab-trastuzumab-phesgo-and-vinorelbine-i-.pdf,2023-08-10,"['Pertuzumab', 'Trastuzumab', 'Vinorelbine']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition', 'Vinca alkaloid chemotherapy']","['Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1154:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and vinorelbine for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.","Pertuzumab in combination with trastuzumab and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf,2023-08-10,"['Pertuzumab', 'Trastuzumab', 'Vinorelbine']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition', 'Vinca alkaloid chemotherapy']","['Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1155:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) for reimbursement as a treatment option for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment. The regime further states that patients should have already been treated with pertuzumab and trastuzumab in combination with DOCEtaxel, PACLItaxel, or vinorelbine.","Pertuzumab/ trastuzumab (Phesgo) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf,2023-08-10,"['Pertuzumab', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition']","['Targeted therapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1156:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, pertuzumab, and trastuzumab for reimbursement as a treatment option for the neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence.","Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf,2023-08-10,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1157:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf,2024-04-27,"['Paclitaxel', 'Nivolumab', 'Carboplatin']",Combination Therapy,"['Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Immunotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1157:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf,2024-04-27,"['Nivolumab', 'Gemcitabine', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Antimetabolite', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1157:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf,2024-04-27,"['Nivolumab', 'Cisplatin', 'Gemcitabine']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antimetabolite']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1157:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf,2024-04-27,"['Pemetrexed', 'Carboplatin', 'Nivolumab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1157:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf,2024-04-27,"['Nivolumab', 'Cisplatin', 'Pemetrexed']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antifolate']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1158:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with weekly carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide for the neoadjuvant treatment, and then continued monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence.","Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/858-pembrolizumab-200mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf,2024-06-04,"['Doxorubicin', 'Paclitaxel', 'Pembrolizumab', 'Cyclophosphamide', 'Carboplatin']",Combination Therapy,"['Topoisomerase inhibition', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Alkylating chemotherapy', 'Platinum-based chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['PR negative [present]', 'HER2-negative [present]', 'ER negative [present]']"
ind:hse.1159:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive metastatic breast cancer.,HER2 positive metastatic breast cancer (MBC).,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf,2022-04-01,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1159:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive early breast cancer.,HER2 positive early breast cancer (EBC).,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf,2022-04-01,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1160:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive metastatic breast cancer.,Treatment of patients with HER2 positive metastatic breast cancer (MBC).,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/201.pdf,2022-04-21,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1161:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the treatment of patients with HER2-negative metastatic breast cancer.,In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf,2021-04-28,"['Paclitaxel', 'Bevacizumab']",Combination Therapy,"['Taxane-based chemotherapy', 'VEGF inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-negative [present]']
ind:hse.1162:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the first-line treatment of patients with HER2-negative metastatic breast cancer.,In combination with PACLitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf,2021-04-28,"['Paclitaxel', 'Bevacizumab']",Combination Therapy,"['Taxane-based chemotherapy', 'VEGF inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-negative [present]']
ind:hse.1162:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with erlotinib for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer with EGFR activating variants.","In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf,2021-04-28,"['Erlotinib', 'Bevacizumab']",Combination Therapy,"['EGFR inhibition', 'VEGF inhibition']","['Targeted therapy', 'Targeted therapy']",['EGFR oncogenic variants [present]']
ind:hse.1163:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved capecitabine for reimbursement as a treatment option for the adjuvant treatment of stage I to IIIB triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.,"Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf,2023-01-18,['Capecitabine'],Monotherapy,['Thymidylate synthase inhibition'],['Chemotherapy'],"['PR negative [present]', 'ER negative [present]', 'HER2-negative [present]']"
ind:hse.1164:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved lapatinib in combination with capecitabine for reimbursement as a treatment option for the treatment of adult patients with advanced or metastatic breast cancer whose tumors overexpress HER2 with disease progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.","Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf,2021-02-10,"['Capecitabine', 'Lapatinib']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1165:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for the adjuvant treatment of estrogen receptor positive breast cancer in patients who are pre- or post-menopausal women.,Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf,2020-11-10,['Tamoxifen'],Monotherapy,['Estrogen receptor inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1165:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for estrogen receptor positive advanced breast cancer in pre- or post-menopausal women.,Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf,2020-11-10,['Tamoxifen'],Monotherapy,['Estrogen receptor inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1166:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.,Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['ER positive [present]', 'HER2-positive [present]', 'PR positive [present]']"
ind:hse.1166:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.,Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-positive [present]', 'ER positive [present]']"
ind:hse.1166:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.,Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-positive [present]', 'PR positive [present]']"
ind:hse.1166:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['ER positive [present]', 'HER2-positive [present]', 'PR positive [present]']"
ind:hse.1166:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-positive [present]', 'ER positive [present]']"
ind:hse.1166:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-positive [present]', 'PR positive [present]']"
ind:hse.1167:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with carboplatin and docetaxel (TCH) - 21 days for reimbursement as a treamtent option for the adjuvant treatment of HER2 positive early breast cancer.,Adjuvant treatment HER2 positive early breast cancer,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/258.pdf,2023-09-04,"['Carboplatin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1168:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) for reimbursement as a monotherapy treatment option for the treatment of HER2 positive metastatic breast cancer (MBC) in patients who have received at least two chemotherapy regimens for their metastatic disease. The indication further notes that prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.","HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf,2021-09-09,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1168:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with paclitaxel for reimbursement as a treatment option for the treatment of HER2 positive metastatic breast cancer in patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.,HER2 positive metastatic breast cancer (MBC) in combination with PACLitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf,2021-09-09,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1168:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with docetaxel as a treatment option for the treatment of HER2 positive metastatic breast cancer for patients who have not received chemotherapy for their metastatic disease.,HER2 positive metastatic breast cancer (MBC) in combination with DOCEtaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf,2021-09-09,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1168:3,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.","HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf,2021-09-09,"['Anastrozole', 'Trastuzumab']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-positive [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1168:3,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.","HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf,2021-09-09,"['Anastrozole', 'Trastuzumab']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-positive [present]', 'ER positive [present]']"
ind:hse.1168:3,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.","HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf,2021-09-09,"['Anastrozole', 'Trastuzumab']",Combination Therapy,"['Aromatase inhibition', 'HER2 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-positive [present]', 'PR positive [present]']"
ind:hse.1169:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable).","HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf,2021-09-09,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1169:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with either paclitaxel or docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide.,"HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with PACLitaxel or DOCEtaxel.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf,2021-09-09,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1169:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with either paclitaxel or docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide.,"HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with PACLitaxel or DOCEtaxel.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf,2021-09-09,"['Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1169:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with adjuvant chemotherapy consisting of carboplatin and docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer.,HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of DOCEtaxel and CARBOplatin.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf,2021-09-09,"['Carboplatin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1169:3,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved neoadjuvant chemotherapy followed by adjuvant trastuzumab for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer for locally advanced (including inflammatory) disease or tumors > 2 cm in diameter. The corresponding European Medicines Agency approval for this indication cites the multicenter randomized trial MO16432, which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy, in the rationale for this approval.","HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours >2cm in diameter.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf,2021-09-09,"['Trastuzumab', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1170:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf,2020-05-13,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1170:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf,2020-05-13,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1170:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.","Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf,2020-05-13,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hse.1171:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC 6) and weekly packlitaxel (80 mg/m^2) followed by dose dense doxorubicin cyclophosphamide for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.,Neoadjuvant treatment of triple negative breast carcinoma.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/348.pdf,2022-09-30,"['Doxorubicin', 'Carboplatin', 'Paclitaxel', 'Cyclophosphamide']",Combination Therapy,"['Topoisomerase inhibition', 'Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'Alkylating chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']","['ER negative [present]', 'PR negative [present]', 'HER2-negative [present]']"
ind:hse.1172:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.","Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf,2020-12-09,['Fulvestrant'],Monotherapy,['Estrogen receptor inhibition'],['Hormone therapy'],['ER negative [present]']
ind:hse.1172:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.","Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf,2020-12-09,['Fulvestrant'],Monotherapy,['Estrogen receptor inhibition'],['Hormone therapy'],['ER negative [present]']
ind:hse.1173:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hse.1173:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1173:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hse.1173:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.,Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hse.1173:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.,Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1173:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.,Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hse.1174:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf,2021-01-06,['Exemestane'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hse.1174:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf,2021-01-06,['Exemestane'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1174:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf,2021-01-06,['Exemestane'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hse.1175:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.,Treatment of locally recurrent metastatic triple negative breast cancer.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf,2023-09-22,"['Carboplatin', 'Gemcitabine']",Combination Therapy,"['Platinum-based chemotherapy', 'Antimetabolite']","['Chemotherapy', 'Chemotherapy']","['ER negative [present]', 'HER2-negative [present]', 'PR negative [present]']"
ind:hse.1176:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved doxorubicin in combination with cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.","Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf,2023-04-17,"['Trastuzumab', 'Cyclophosphamide', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Alkylating chemotherapy', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1176:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved doxorubicin in combination with cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th) for reimbursement as a treatment option for the neoadjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.","Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf,2023-04-17,"['Trastuzumab', 'Cyclophosphamide', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Alkylating chemotherapy', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1177:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved paclitaxel (80) in combination with trastuzumab therapy - 7 day (12 weeks) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, node-negative breast cancer of tumor size <= 3 cm.","Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumour size <= 3cm.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdf,2022-11-29,"['Trastuzumab', 'Paclitaxel']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy']","['Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hse.1179:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab for reimbursement as a treatment option for the maintenance treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in adult patients, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.","Pertuzumab in combination with trastuzumab for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf,2024-05-29,"['Pertuzumab', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition']","['Targeted therapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1180:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, trastuzumab (s/c), and pertuzumab (tch(s/c)p) therapy for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.","Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf,2023-08-10,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1181:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC2) weekly in combination with paclitaxel 80 mg/m^2 followed by dose dense doxorubicin cyclophosphamide therapy for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.,Neoadjuvant treatment of triple negative breast carcinoma,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/734-carboplatin-auc-2-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-cyclophosphamide-therapy-triple-negative-breast-cancer-therapy.pdf,2024-05-27,"['Doxorubicin', 'Carboplatin', 'Paclitaxel', 'Cyclophosphamide']",Combination Therapy,"['Topoisomerase inhibition', 'Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'Alkylating chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']","['ER negative [present]', 'PR negative [present]', 'HER2-negative [present]']"
ind:hse.1182:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab, paclitaxel, and carboplatin (TRAIN-2) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive, locally advanced, inflammastory, or early stage breast cancer at high risk of recurrence in adult patients.","Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf,2023-08-10,"['Carboplatin', 'Trastuzumab', 'Paclitaxel', 'Pertuzumab']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1183:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with carboplatin and docetaxel (TCHP) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.","Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf,2024-06-07,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hse.1184:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab 200mg in combination with carboplatin (AUC 5) and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (AC 60/600) for reimbursement as a treatment option for the neoadjuvant treatment, and then pembrolizumab as a monotherapy treatment as an adjuvant treatment after surgery, of locally advanced or early stage triple negative breast cancer at high risk of recurrence in adult patients.","Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf,2024-06-04,"['Doxorubicin', 'Paclitaxel', 'Pembrolizumab', 'Cyclophosphamide', 'Carboplatin']",Combination Therapy,"['Topoisomerase inhibition', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Alkylating chemotherapy', 'Platinum-based chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['PR negative [present]', 'HER2-negative [present]', 'ER negative [present]']"
ind:hse.1185:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved dose dense doxorubicin in combination with cyclophosphamide (AC 60/600) 14 day followed by weekly paclitaxel (80) and weekly trastuzumab (DD AC-TH) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.","Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/dose-dense-acth-433.pdf,2023-10-18,"['Trastuzumab', 'Cyclophosphamide', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Alkylating chemotherapy', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1185:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved dose dense doxorubicin in combination with cyclophosphamide (AC 60/600) 14 day followed by weekly paclitaxel (80) and weekly trastuzumab (DD AC-TH) for reimbursement as a treatment option for the neoadjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.","Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/dose-dense-acth-433.pdf,2023-10-18,"['Trastuzumab', 'Cyclophosphamide', 'Paclitaxel', 'Doxorubicin']",Combination Therapy,"['HER2 inhibition', 'Alkylating chemotherapy', 'Taxane-based chemotherapy', 'Topoisomerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1186:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 day) for reimbursement as a monotherapy treatment option for the treatment of epidermal growth factor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) which has failed oxaliplatin- and irinotecan-based therapy that is intolerant to irinotecan in adult patients. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",As monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/207.pdf,2020-02-12,['Cetuximab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['Wild type NRAS [present]', 'Wild type KRAS [present]', 'EGFR positive [present]']"
ind:hse.1187:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab for reimbursement as a monotherapy treatment option for the treatment of wild-type RAS metastatic colorectal cancer (mCRC) after failure of fluoropyrimidine, oxaliplatin, and irinotecan containig chemotherapy regimens in adult patients. The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.","Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy regimens.",Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf,2020-11-10,['Panitumumab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:hse.1188:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",Treatment of patients with RAS wild type metastatic colorectal cancer.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf,2023-11-23,"['Fluorouracil', 'Irinotecan', 'Cetuximab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']","['Wild type NRAS [present]', 'Wild type KRAS [present]']"
ind:hse.1189:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with irinotecan (14 days) for reimbursement as a treatment option for the second line treatment of adult patients with metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/330-cetuximab-7days-and-irinotecan-14-days-therapy.pdf,2022-01-17,"['Irinotecan', 'Cetuximab']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Targeted therapy']","['Wild type NRAS [present]', 'Wild type KRAS [present]']"
ind:hse.1190:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with irinotecan (14 days) for reimbursement as a treatment option for the second line treatment of adult patients with metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/331-cetuximab-14-days-and-irinotecan-14-days-therapy-.pdf,2022-01-17,"['Irinotecan', 'Cetuximab']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Targeted therapy']","['Wild type NRAS [present]', 'Wild type KRAS [present]']"
ind:hse.1191:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6 mg/kg in combination with modified FOLFOX-6 (14 day) for reimbursement as a treatment option for the first line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/447.pdf,2023-11-21,"['Fluorouracil', 'Panitumumab', 'Oxaliplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'EGFR inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type NRAS [present]', 'Wild type KRAS [present]']"
ind:hse.1192:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6mg/kg in combination with FOLFIRI (14 day) for reimbursement as a treatment option for the first line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448%20panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf,2023-11-21,"['Irinotecan', 'Panitumumab', 'Fluorouracil']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:hse.1192:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6mg/kg in combination with FOLFIRI (14 day) for reimbursement as a treatment option for the second line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) who have received first-line fluoropyrimidinebased chemotherapy (excluding irinotecan). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448%20panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf,2023-11-21,"['Irinotecan', 'Panitumumab', 'Fluorouracil']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:hse.1193:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with 5-fluorouracil and cisplatin (21 days) as a treatment option for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.,Treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.,Esophagogastric Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/502trastuzumab-5-fluorouracil-and-cisplatin-therapy-21.pdf,2023-11-21,"['Fluorouracil', 'Trastuzumab', 'Cisplatin']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition', 'Platinum-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hse.1194:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (14 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",Treatment of patients with RAS wild type metastatic colorectal cancer.,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/585.pdf,2023-11-21,"['Fluorouracil', 'Irinotecan', 'Cetuximab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']","['Wild type NRAS [present]', 'Wild type KRAS [present]']"
ind:hse.1195:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab (240 mg) in combination with fluoropyrimidine and platinum-based combination chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell programmed death ligand 1 (PD-L1) expression >= 1%. This regimen specifically cites cisplatin and 5-fluorouracil as the chemotherapy.","Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression >= 1%.",Esophageal Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/816-nivolumab-cisplatin.pdf,2023-11-21,"['Fluorouracil', 'Cisplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1196:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell programmed death ligand 1 (PD-L1) expression >= 1%. This regimen specifically cites cisplatin and 5-fluorouracil as the chemotherapy.","Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression >= 1%.",Esophageal Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/844-nivolumab-and-folfox-6-modified-therapy.pdf,2024-02-20,"['Fluorouracil', 'Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1197:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.,First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1197:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy whose tumors express PD-L1 with a combined positive score (CPS) >= 10.,As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) >= 10.,Bladder Urothelial Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 10 [present]']
ind:hse.1197:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.,As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1,Head and Neck Squamous Cell Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 1 [present]']
ind:hse.1197:3,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.","As monotherapy for the treatment of recurrent, or metastatic cervical cancer with disease progression on or after chemotherapy in adults whose tumours express PD-L1 with a CPS >= 1",Cervical Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 1 [present]']
ind:hse.1197:4,hse,The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).,First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults,Colorectal Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf,2023-04-01,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:hse.1198:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with paclitaxel (175 mg/m^2), carboplatin (AUC-5), and bevacizumab for reimbursement as a treatment option for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1.","Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.",Cervical Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/811-pembrolizumab-paclitaxel-carboplatin-auc.pdf,2023-04-17,"['Pembrolizumab', 'Paclitaxel', 'Bevacizumab', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'VEGF inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hse.1199:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with paclitaxel (175 mg/m^2) and carboplatin (AUC-5) for reimbursement as a treatment option for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1.","Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.",Cervical Adenocarcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/817-pembrolizumab-paclitaxel-carboplatin-auc-5-therapy.pdf,2023-04-17,"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hse.1200:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with ofatumumab for reimbursement as a treatment option for the first line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf,2019-02-11,"['Ofatumumab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['TP53 somatic variants [present]']
ind:hse.1200:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with ofatumumab for reimbursement as a treatment option for the first line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf,2019-02-11,"['Ofatumumab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['TP53 deletion [present]']
ind:hse.1200:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with ofatumumab for reimbursement as a treatment option for the first line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.,Chronic Lymphocytic Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf,2019-02-11,"['Ofatumumab', 'Idelalisib']",Combination Therapy,"['CD20 inhibition', 'PI3K/AKT/mTOR inhibition']","['Immunotherapy', 'Targeted therapy']",['17p deletion []']
ind:hse.1201:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin as a single agent for reimbursement as a treatment option for the maintenance treatment of adult patients with FLT3 mutation positive acute myeloid leukemia (AML) in complete response after completion of induction and consolidation chemotherapy.,Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.,Acute Myeloid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf,2023-12-08,['Midostaurin'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3-ITD [present]']
ind:hse.1202:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin in combination with intermediate dose cytarabine consolidation chemotherapy for reimbursement as a treatment option for the treatment of adult patients newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation positive,Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive,Acute Myeloid Leukemia,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf,2023-12-08,['Midostaurin'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3-ITD [present]']
ind:hse.1203:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine (1250mg/m^2) in combination with cisplatin (75mg/m^2) (21 day) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.3).,In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.3),Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf,2024-05-01,"['Nivolumab', 'Cisplatin', 'Gemcitabine']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antimetabolite']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1204:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved paclitaxel (200mg/m^2) in combination with carboplatin (AUC 6) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.1).,In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.1),Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf,2024-05-01,"['Nivolumab', 'Paclitaxel', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1205:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine (1000mg/m^2) in combination with carboplatin (AUC 5) (21 day) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.2).,In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.2),Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf,2024-05-01,"['Nivolumab', 'Gemcitabine', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Antimetabolite', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1206:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with cisplatin and pemetrexed for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.5).,In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.5),Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf,2024-05-01,"['Nivolumab', 'Pemetrexed', 'Cisplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1207:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with carboplatin and pemetrexed for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.4).,In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.4),Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf,2024-05-01,"['Nivolumab', 'Carboplatin', 'Pemetrexed']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'Antifolate']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 >= 1% [present]']
ind:hse.1208:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.,Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression >= 5%.,Bladder Urothelial Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf,2024-02-19,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 5% [present]']
ind:hse.1208:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf,2024-02-19,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1208:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression >= 50% tumour cells (TC) or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf,2024-02-19,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'PD-L1 >= 10% TIIC [present]', 'Wild type EGFR [present]']"
ind:hse.1208:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.,Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.,Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf,2024-02-19,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hse.1209:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved durvalumab for reimbursement as a monotherapy treatment option for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).","As monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf,2023-09-04,['Durvalumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 1% [present]']
ind:hse.1210:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (21 days) for reimbursement as a treatment option for the treatemnt of patients with CD20 positive non-Hodgkin's lymphoma. This indication is also generally for cyclophosphamide, doxorubicin, vincristine, and prednisolone as a treatment option for patients non-Hodgkin's lymphoma, and the treatment regimen notes that rituximab should be included for CD20+ patients.",Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf,2023-09-04,"['Doxorubicin', 'Vincristine', 'Cyclophosphamide', 'Prednisolone', 'Rituximab']",Combination Therapy,"['Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Alkylating chemotherapy', 'Corticosteroid', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1211:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).","Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).",Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf,2021-04-28,"['Bendamustine', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'CD20 inhibition']","['Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1211:1,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.","Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.",Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf,2021-04-28,"['Bendamustine', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'CD20 inhibition']","['Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1212:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cisplatin in combination with cytarabine, dexamethasone, and granulocyte colony stimulating factor (G-CSF) (DHAP Therapy) for reimbursement as a treatment option for the treatment of patients with relapsed Non Hodgkin Lymphoma (NHL). The regimen specification also states that rituximab should be included for treatment of CD20 positive patients.",Treatment of relapsed Non Hodgkin Lymphoma. Rituximab to be included in CD20 positive patients.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf,2022-06-27,"['Cisplatin', 'Cytarabine', 'Rituximab']",Combination Therapy,"['Platinum-based chemotherapy', 'DNA Polymerase inhibition', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1213:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab in combination with etoposide, prednisolone, doxorubicin, cyclophosphamide and vincristine (DA-R EPOCH) therapy for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins Lymphoma (NHL).",Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).,Diffuse Large B-Cell Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdf,2023-11-06,"['Cyclophosphamide', 'Doxorubicin', 'Prednisolone', 'Vincristine', 'Etoposide', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid', 'Vinca alkaloid chemotherapy', 'Topoisomerase inhibition', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1213:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab in combination with etoposide, prednisolone, doxorubicin, cyclophosphamide and vincristine (DA-R EPOCH) therapy for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins Lymphoma (NHL).",Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdf,2023-11-06,"['Cyclophosphamide', 'Doxorubicin', 'Prednisolone', 'Vincristine', 'Etoposide', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid', 'Vinca alkaloid chemotherapy', 'Topoisomerase inhibition', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1214:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin in combination with ifosfamide and etoposide (ICE) for reimbursement as a treatment option for the treatment of relapsed/refractory Non Hodgkin's Lymphoma. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.,Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf,2022-09-21,"['Ifosfamide', 'Carboplatin', 'Etoposide', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'Platinum-based chemotherapy', 'Topoisomerase inhibition', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1215:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (CHOP Therapy) (14 days) for the treatment of non-hodgkin's lymphoma (NHL). The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.",Treatment of Non Hodgkin's Lymphoma (NHL). Rituximab to be included in CD20 positive patients.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf,2024-07-05,"['Vinorelbine', 'Cyclophosphamide', 'Doxorubicin', 'Prednisolone', 'Rituximab']",Combination Therapy,"['Vinca alkaloid chemotherapy', 'Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1216:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (mini-CHOP Therapy) (21 days) for the treatment of non-hodgkin lymphoma (NHL) in patients aged greater than 80 or with significant co-morbidities. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.",Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities. Rituximab to be included in all CD20 positive patients.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf,2023-11-01,"['Vinorelbine', 'Cyclophosphamide', 'Doxorubicin', 'Prednisolone', 'Rituximab']",Combination Therapy,"['Vinca alkaloid chemotherapy', 'Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1217:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.,Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.,Diffuse Large B-Cell Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf,2020-08-19,"['Oxaliplatin', 'Gemcitabine', 'Rituximab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antimetabolite', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1217:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.,Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf,2020-08-19,"['Oxaliplatin', 'Gemcitabine', 'Rituximab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antimetabolite', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1218:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.",Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf,2021-02-03,"['Cyclophosphamide', 'Prednisolone', 'Etoposide', 'Vincristine', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'Corticosteroid', 'Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1219:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with bendamustine for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).,Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).,Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf,2019-10-18,"['Brentuximab Vedotin', 'Bendamustine']",Combination Therapy,"['target CD30 antigens', 'Alkylating chemotherapy']","['Targeted therapy', 'Chemotherapy']",['CD30 + [present]']
ind:hse.1220:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.,Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf,2021-03-31,"['Rituximab', 'Cyclophosphamide', 'Vincristine', 'Prednisolone']",Combination Therapy,"['CD20 inhibition', 'Alkylating chemotherapy', 'Vinca alkaloid chemotherapy', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hse.1220:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.,Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf,2021-03-31,"['Rituximab', 'Cyclophosphamide', 'Doxorubicin', 'Vincristine', 'Prednisolone']",Combination Therapy,"['CD20 inhibition', 'Alkylating chemotherapy', 'Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hse.1220:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.,Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf,2021-03-31,"['Rituximab', 'Mitoxantrone', 'Chlorambucil', 'Prednisolone']",Combination Therapy,"['CD20 inhibition', 'Topoisomerase inhibition', 'Alkylating chemotherapy', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hse.1220:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.,Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf,2021-03-31,"['Interferon Alpha', 'Etoposide', 'Rituximab', 'Cyclophosphamide', 'Doxorubicin', 'Prednisolone']",Combination Therapy,"['Cytokine stimulation', 'Topoisomerase inhibition', 'CD20 inhibition', 'Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hse.1221:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.","Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf,2021-03-31,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1221:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.","Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf,2021-03-31,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1222:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (84 day) for reimbursement as a treatment option for the maintenance treatment of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients who have responded to induction therapy.","Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.",Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf,2022-10-12,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1222:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (84 day) for reimbursement as a treatment option for the maintenance treatment of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients who have responded to induction therapy.","Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.",Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf,2022-10-12,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1223:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.","Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf,2022-10-12,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1223:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.","Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf,2022-10-12,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1224:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.",Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).,Diffuse Large B-Cell Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf,2023-11-06,"['Cyclophosphamide', 'Doxorubicin', 'Prednisolone', 'Vincristine', 'Etoposide', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid', 'Vinca alkaloid chemotherapy', 'Topoisomerase inhibition', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1224:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.",Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf,2023-11-06,"['Cyclophosphamide', 'Doxorubicin', 'Prednisolone', 'Vincristine', 'Etoposide', 'Rituximab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'Corticosteroid', 'Vinca alkaloid chemotherapy', 'Topoisomerase inhibition', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hse.1225:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the first line treatment of patients with low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.,First line treatment of patients with low grade B cell Non Hodgkin's lymphoma (NHL). Rituximab to be included in CD20 positive patients.,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf,2022-06-27,"['Rituximab', 'Cyclophosphamide', 'Vincristine', 'Prednisolone']",Combination Therapy,"['CD20 inhibition', 'Alkylating chemotherapy', 'Vinca alkaloid chemotherapy', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hse.1225:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the treatment of patients with relapsed / refractory low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.,Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin's lymphoma (NHL).,Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf,2022-06-27,"['Rituximab', 'Cyclophosphamide', 'Vincristine', 'Prednisolone']",Combination Therapy,"['CD20 inhibition', 'Alkylating chemotherapy', 'Vinca alkaloid chemotherapy', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hse.1226:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.","Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.",Follicular Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf,2021-03-31,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1226:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.","Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.",Non-Hodgkin Lymphoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf,2021-03-31,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hse.1227:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).,Gastrointestinal Stromal Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf,2020-07-15,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['CD117 + [present]']
ind:hse.1227:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).,Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.,Gastrointestinal Stromal Tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf,2020-07-15,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['CD117 + [present]']
ind:hse.1228:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved tepotinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/823-tepotinib-therapy.pdf,2024-08-01,['Tepotinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Splice Site) [present]']
ind:hse.1228:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved tepotinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.","As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",Non-Small Cell Lung Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/823-tepotinib-therapy.pdf,2024-08-01,['Tepotinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Deletion) [present]']
ind:hse.1229:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab deruxtecan (Enhertu) for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.,As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/776-trastuzumab-deruxtecan-enhertu-therapy.pdf,2024-08-01,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hse.1230:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg, carboplatin AUC 5, and weekly paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.","Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/860-pembrolizumab-400mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf,2024-06-01,"['Doxorubicin', 'Paclitaxel', 'Pembrolizumab', 'Cyclophosphamide', 'Carboplatin']",Combination Therapy,"['Topoisomerase inhibition', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Alkylating chemotherapy', 'Platinum-based chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['PR negative [present]', 'HER2-negative [present]', 'ER negative [present]']"
ind:hse.1231:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg in combination with weekly carboplatin AUC 1.5 and paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.","Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/861-pembrolizumab-400mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf,2024-07-18,"['Doxorubicin', 'Paclitaxel', 'Pembrolizumab', 'Cyclophosphamide', 'Carboplatin']",Combination Therapy,"['Topoisomerase inhibition', 'Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition', 'Alkylating chemotherapy', 'Platinum-based chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['PR negative [present]', 'HER2-negative [present]', 'ER negative [present]']"
ind:hse.1232:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved vandetanib for reimbursement as a monotherapy treatment option for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) that is Rearranged during Transfection (RET) mutation positive.","Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.",Medullary Thyroid Cancer,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf,2023-02-07,['Vandetanib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:hse.1233:0,hse,The Republic of Ireland's Health Service Executive (HSE) has approved tretinoin (ATRA) with arsenic trioxide (ATO) for reimbursement as a treatment option for the treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC <= 10x10^9L). This regimen contains the eligibility criteria of a clinical diagnosis of APL and subsequently confirmed to have PML::RARA rearrangements by a valid test method.,Treatement of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count <= 10x10^9/L),APL with PML-RARA,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf,2023-09-20,['Arsenic trioxide'],Monotherapy,['PML::RARA inhibition'],['Targeted therapy'],['PML::RARA [present]']
ind:hse.1233:1,hse,The Republic of Ireland's Health Service Executive (HSE) has approved tretinoin (ATRA) with arsenic trioxide (ATO) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory Acute Promyelocytic Leukaemia (APL) after ATRA/chemotherapy. This regimen contains the eligibility criteria of a clinical diagnosis of APL and subsequently confirmed to have PML::RARA rearrangements by a valid test method.,Treatement of patients with relapsed or refractory APL after ATRA/chemotherapy,APL with PML-RARA,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf,2023-09-20,['Arsenic trioxide'],Monotherapy,['PML::RARA inhibition'],['Targeted therapy'],['PML::RARA [present]']
ind:hse.1234:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved sacituzumab govitecan for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.","As monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/794-sacituzumab-govitecan-therapy.pdf,2024-08-29,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'PR negative [present]', 'ER negative [present]']"
ind:hse.1235:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.","For the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who: (i) have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf,2024-10-01,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:hse.1235:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.","For the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who: (i) have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf,2024-10-01,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:hse.1235:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.","For the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who: (i) have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.",Any solid tumor,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf,2024-10-01,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:hpra.arimidex:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.,Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra.arimidex:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.,Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hpra.arimidex:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.,Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['ER positive [present]', 'PR positive [present]']"
ind:hpra.arimidex:1,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.,Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra.arimidex:1,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.,Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hpra.arimidex:1,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.,Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['ER positive [present]', 'PR positive [present]']"
ind:hpra.arimidex:2,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.,Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra.arimidex:2,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.,Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hpra.arimidex:2,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.,Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf,2021-06-09,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['ER positive [present]', 'PR positive [present]']"
ind:hse.1166:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1166:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hse.1166:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf,2020-11-10,['Anastrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['ER positive [present]', 'PR positive [present]']"
ind:hpra.aromasin:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized exemestane for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive invasive early breast cancer (EBC) who have received 2 to 3 years of initial tamoxifen therapy.,"Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer (EBC), following 2  3 years of initial adjuvant tamoxifen therapy.",Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf,2022-06-10,['Exemestane'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra:femara:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra:femara:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hpra:femara:0,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.,Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hpra:femara:1,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra:femara:1,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hpra:femara:1,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hpra:femara:2,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.,First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hpra:femara:2,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.,First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hpra:femara:2,hpra,The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.,First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.,Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hpra:femara:3,hpra,"The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.","Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.",Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-negative [present]', 'ER positive [present]']"
ind:hpra:femara:3,hpra,"The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.","Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.",Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-negative [present]', 'PR positive [present]']"
ind:hpra:femara:3,hpra,"The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.","Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.",Invasive Breast Carcinoma,https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf,2024-08-30,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1173:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior adjuvant treatment for 5 years.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1173:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior adjuvant treatment for 5 years.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hse.1173:2,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior adjuvant treatment for 5 years.,Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.,Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hse.1173:3,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the treatment of patients who are women with natural or artificially induced postmenopausal endocrine status with advanced breast cancer after relapse or disease progression. This therapy regimen lists hormone receptor-negative status as an exclusion criteria.,"Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['ER positive [present]']
ind:hse.1173:3,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the treatment of patients who are women with natural or artificially induced postmenopausal endocrine status with advanced breast cancer after relapse or disease progression. This therapy regimen lists hormone receptor-negative status as an exclusion criteria.,"Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],['PR positive [present]']
ind:hse.1173:3,hse,The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the treatment of patients who are women with natural or artificially induced postmenopausal endocrine status with advanced breast cancer after relapse or disease progression. This therapy regimen lists hormone receptor-negative status as an exclusion criteria.,"Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf,2020-12-09,['Letrozole'],Monotherapy,['Aromatase inhibition'],['Hormone therapy'],"['PR positive [present]', 'ER positive [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'ER positive [present]', 'HER2-negative [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hse.1178:0,hse,"The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf,2024-05-31,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Anastrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Abemaciclib', 'Letrozole']",Combination Therapy,"['CDK4/6 inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:ema.verzenios:0,ema,"The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.",Invasive Breast Carcinoma,https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf,2024-03-12,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
